EIP Coffee BreakUpdates and Changes
2021年8月24日

China Finally Clamps Down on Facial Recognition Technology

Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape

Around the end of July 2021, the Supreme People’s Court issued a new Provision concerning the application of law about a super-hot technology, facial recognition. This Provision is a legal explanation from the SPC explaining how the law should be applied or interpreted in a litigation.

This Provision emphasizes that facial information is sensitive biometric information. It is considered a type of personal information having the strongest social attributes, yet at the same time it is very easy to collect. It is fundamentally unique and unchangeable. Once leaked, it will cause extreme damage to individuals’ personal safety and property, and may even threaten public safety. Most importantly, the Provision emphasizes that protection of personal information is of great importance, and provides a lot more clarity on how various types of facial recognition technology would be considered with respect to their impact on an individual’s personal privacy rights.

We welcome such a change: China is finally becoming serious about personal information protection after so many years. This Provision will have a huge impact on the implementation of patents that use facial recognition technologies, and in turn will affect the value of such patents. As for whether it will affect such patent applications from the administrative order level, we will observe and see what happens now that the Provision has formally been implemented (1 Aug 2021).

Source: 最高法发布审理使用人脸识别技术处理个人信息相关民事案件的司法解释

About the Authors

Yolanda Wang is a Principal, Chinese Patent Attorney, and Chinese Patent Litigator at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

2025年4月1日
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]

我们的过去活动

Top crossarrow-right